Analyzing Black Diamond Therapeutics (NASDAQ:BDTX) and Entrada Therapeutics (NASDAQ:TRDA)

Entrada Therapeutics (NASDAQ:TRDA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Entrada Therapeutics and Black Diamond Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Insider & Institutional Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Entrada Therapeutics and Black Diamond Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1	1	4	0	2.50
Black Diamond Therapeutics	1	2	7	0	2.60

Entrada Therapeutics currently has a consensus price target of $17.75, indicating a potential upside of 290.11%. Black Diamond Therapeutics has a consensus price target of $11.00, indicating a potential upside of 547.06%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Entrada Therapeutics.

Volatility & Risk

Entrada Therapeutics has a beta of -0.24, suggesting that its share price is 124% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.32, suggesting that its share price is 232% more volatile than the S&P 500.

Valuation and Earnings

This table compares Entrada Therapeutics and Black Diamond Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42 million	6.97	-$143.75 million	($3.96)	-1.15
Black Diamond Therapeutics	N/A	N/A	$22.37 million	($0.75)	-2.27

Black Diamond Therapeutics has lower revenue, but higher earnings than Entrada Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Black Diamond Therapeutics beats Entrada Therapeutics on 10 of the 12 factors compared between the two stocks.

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.